HROW News and Press, Harrow Health Inc. From 04/02/24

MELT-300 Pivotal Phase 3 Program Topline Readout Expected in Q4 2024 Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of its Series B Preferred Stock fina...

2024-03-20 10:14:11 ET Harrow, Inc. (HROW) Q4 2023 Earnings Conference Call March 20, 2024 08:00 A.M. ET Company Participants Jamie Webb - Director-Communications & IR Mark L. Baum - Chairman and CEO Andrew R. Boll - CFO Conference Call Participants ...

2024-03-20 08:11:18 ET More on pre-market losers & stocks. Prudential: Consider Both Upcoming Results And 2024 Risk Factors Euronav NV: Not Backing Down On The Decarbonization Agenda Euronav NV 2023 Q4 - Results - Earnings Call Presentation Solidion Techn...

2024-03-20 01:11:43 ET More on Harrow Health Harrow's Drug Iheezo Is Off To A Great Start Harrow: Hedge Downside Risk With The 11.5% Yielding Baby Bonds Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity Harrow says dry eye drug Vevye n...

Full-Year 2023 Highlights: Revenues of $130.2 million, an increase of 47% over 2022 revenues of $88.6 million. GAAP net loss of $(24.4 million) compared with $(14.1 million) for the prior-year period. Adjusted EBITDA of $28.1 million, an increase of 116% over 2022 Adjusted EBITDA of...

Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...

2024-03-18 17:35:27 ET More on etc. A Bitcoin Strategy Using The 200-Day Simple Moving Average (Technical Analysis) Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead Re-Emerging Markets Biggest stock movers today: NVDA, GOOG, FOUR and more ...

2024-03-18 17:35:14 ET More on Harrow Health Harrow's Drug Iheezo Is Off To A Great Start Harrow: Hedge Downside Risk With The 11.5% Yielding Baby Bonds Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity Harrow says dry eye drug Vevye n...

Company to Host Conference Call to Discuss Results at 8:00 a.m. ET on March 20, 2024 Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2023, on Tue...

2024-03-02 14:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...